Physician profile
Peter Rumore
NPI 1245226109
$12,010.54
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,680 · 2020: $850 · 2021: $1,918 · 2022: $3,727 · 2023: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,410.87 | 2019-2023 | Rinvoq, Skyrizi |
| Amgen INC. | $1,890.98 | 2019-2023 | Tavneos, Enbrel, Amjevita |
| Janssen Biotech, INC. | $975.29 | 2019-2023 | Simponi Aria, Tremfya |
| Pfizer INC. | $956.28 | 2019-2023 | |
| Ucb, INC. | $751.43 | 2019-2023 | Cimzia |
| Lilly USA, LLC | $712.49 | 2019-2023 | Taltz |
| Genentech USA, INC. | $531.37 | 2019-2023 | Rituxan, Actemra |
| Horizon Therapeutics Plc | $502.71 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $499.49 | 2019-2023 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $415.78 | 2021-2023 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $354.99 | 2019-2023 | |
| Mallinckrodt Enterprises LLC | $328.09 | 2019 | |
| Aurinia Pharma U.S., INC. | $294.53 | 2021-2023 | Lupkynis |
| Radius Health, INC. | $289.46 | 2019-2023 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $170.00 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.49 | 2022-2023 | Ofev |
| Ferring Pharmaceuticals INC. | $120.80 | 2022-2023 | Euflexxa |
| Pacira Therapeutics, INC. | $104.04 | 2019-2021 | |
| Depuy Synthes Sales INC. | $96.19 | 2019-2021 | |
| Antares Pharma, INC. | $86.92 | 2019 | |
| Medexus Pharma, INC. | $71.51 | 2019-2020 | |
| Sobi, INC | $51.10 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $46.55 | 2023 | Arcalyst |
| Celgene Corporation | $44.42 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.92 | 2022-2023 | Orencia |
| Fidia Pharma USA INC. | $27.17 | 2019-2023 | Hym/Hyn |
| Ani Pharmaceuticals, INC. | $24.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.76 | 2019 | |
| Grt US Holding, INC. | $19.61 | 2021 | |
| Sandoz INC. | $14.23 | 2023 | |
| Genzyme Corporation | $14.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rumore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.